Maravai LifeSciences Announces November 2025 Investor Conference Schedule

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a prominent provider of life science reagents and services, has announced its participation in two significant investor conferences in November 2025. On November 12, at 10:00 a.m. EST, CFO Raj Asarpota will engage in a fireside chat at the Stifel Healthcare Conference held in New York City. Following that, on November 19 at 10:00 a.m. GMT, he will participate in another fireside chat at the Jefferies Healthcare Conference in London.

Both presentations aim to provide investors and stakeholders with insights into Maravai's strategies, growth prospects, and market positioning. Interested parties will have the opportunity to access a live webcast of each session via the Maravai LifeSciences Investor Relations website, under the News & Events section. Furthermore, archived versions of the webcasts will be available post-event for those unable to attend live.

Maravai LifeSciences focuses on enabling drug therapies, diagnostics, and novel vaccines, supporting research on human diseases. The company's subsidiaries excel in nucleic acid synthesis and biologics safety testing, catering to leading biopharmaceutical, vaccine, diagnostics, and gene and cell therapy organizations worldwide.

For more detailed information about Maravai LifeSciences, stakeholders and interested individuals are encouraged to visit the company's official website at www.maravai.com.

The participation of Maravai in these notable conferences highlights its commitment to transparency and engagement with investors, reinforcing its position within the biotechnology sector. For further inquiries or additional details, investors can reach out to Deb Hart at Maravai LifeSciences via email or phone.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) is proactively engaging with investors through its scheduled appearances at both the Stifel Healthcare Conference and the Jefferies Healthcare Conference in November 2025. These events represent a strategic opportunity for the company, notably through CFO Raj Asarpota's participation, which can provide insights into Maravai's operations, financial outlook, and growth trajectory in the life sciences sector.

Maravai is positioned in a robust market landscape, focusing on crucial segments like nucleic acid synthesis and biologics safety testing. These fields are critical for the development of drug therapies and novel vaccines, making Maravai an important player as the biopharmaceutical sector continues to expand. With ongoing advancements in healthcare needs, the demand for reliable and innovative life science reagents is expected to grow exponentially. Consequently, investors should view Maravai as a potential growth opportunity, particularly as it continues to partner with major biopharmaceutical companies.

As you consider investment in Maravai, pay attention to the information disseminated during the upcoming conferences. Webcasts will provide valuable insights that can influence short- to medium-term stock performance, especially if the discussions lead to positive market sentiments or new strategic initiatives.

It is crucial for potential investors to analyze the company's financial health, product pipeline, and market conditions alongside the developments highlighted in these presentations. Monitoring Maravai's post-conference performance and investor responses will be key indicators of market sentiment and growth prospects. Overall, with an emphasis on innovation, strategic leadership, and robust market demand, Maravai LifeSciences presents a compelling narrative for investors looking to capitalize on the burgeoning life sciences industry.